5 Big Winners and Losers From Earnings Season: Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), Eli Lilly & Co. (LLY)

Page 1 of 2

Earnings season is a wrap for many of the brightest stars of the health care sector: Big pharma’s big disappointments and successes are in the books, and investors are looking ahead to the future. Patent expirations have been taking their toll on sales of some of the industry’s biggest blockbuster drugs lately, putting pharmaceutical firms on the defensive as they try to boost pipeline stockpiles and stave off revenue losses. With that in mind, how did five of big pharma’s biggest names grade out this earnings season?

Pfizer Inc. (NYSE:PFE)Earnings season’s big winner: Pfizer Inc. (NYSE:PFE)
After a great 2012, Pfizer Inc. (NYSE:PFE) has opened up 2013 with a bang. The company’s $11.85 billion sale of its nutrition business to Nestle last year has rewarded shareholders, as Pfizer reported fourth-quarter profit that more than quadrupled last year’s total. Earnings per share of $0.85 — drastically up from $0.19 a year ago — made investors happy, although adjusted EPS that removed one-time items fell slightly by $0.02 to $0.47; still, that beat analyst profit projections of $0.44 per share for the quarter.

All the talk now surrounds Pfizer’s recent debut of former animal health business Zoetis Inc (NYSE:ZTS) as a publicly traded company following its recent IPO, but Pfizer’s still dealing with issues of its own. The company faces plenty of generic competition for drugs — particularly blockbuster Lipitor, which lost patent protection last year — in what’s become an industrywide trend. However, with a massive pipeline of 87 drugs to bolster the future, Pfizer could make up for falling revenues, which declined 7% this past quarter, by scoring a few timely FDA approvals.

Ultimately, Pfizer could be one of the better-positioned companies for the future after it scored one of the industry’s best earnings reports, particularly as its rivals have struggled as of late.

Future imperfect: Merck & Co., Inc. (NYSE:MRK)
Fellow Dow Jones member Merck & Co., Inc. (NYSE:MRK) hasn’t had so much to cheer about recently despite a strong 2012. The company actually reported an earnings beat despite the negativity that’s surrounded it in past days; Merck’s earnings per share came in at $0.83, $0.02 higher than analysts projected, while revenue of $11.7 billion also beat expectations. Both fell from a year ago — and it’s the future, not the present, that has investors so concerned.

The company warned investors that generic competition will cut into 2013 profits as Merck continues to feel the pain from patent expirations, particularly on blockbuster drug Singulair. The company’s still got a handle on strong products for the future, such as blockbuster diabetes therapies Januvia and Janumet and fast-growing cervical cancer vaccine Gardasil — each of which posted strong ┬ádouble-digit sales growth this past quarter — but the caution wasn’t what shareholders wanted to hear.

Singulair sales flopped by 67% this past quarter — and by 30% for 2012 as a whole — showing just how bad the patent cliff is hurting Merck’s sales. With the company delaying its filing for FDA approval on promising osteoporosis drug odanacatib until 2014, the year ahead for Merck has become considerably tougher.

The pain of patent losses: Eli Lilly & Co. (NYSE:LLY) and Bristol Myers Squibb Co. (NYSE:BMY)
Generic sales have cut a wide swath across big pharma with the patent cliff, and Eli Lilly & Co. (NYSE:LLY) and Bristol Myers Squibb Co. (NYSE:BMY) felt the pain this quarter. The former’s still feeling the pain from the 2011 patent expiration of once-blockbuster drug Zyprexa, as the drug’s sales fell 49% in the fourth quarter to under $400 million — after at one point selling more than $5 billion annually. Eli Lilly’s earnings per share fell by $0.03 year-over-year to $0.74 for the quarter, with revenue also falling around 1%. Still, the company’s numbers did manage to beat estimates. Furthermore, Eli Lilly’s pipeline holds several promising therapies in oncology and diabetes that could help the stock’s recent run-up should any of them score FDA approval and would ease the loss of patent protection on blockbuster depression drug Cymbalta this December.

Bristol-Myers managed to boost earnings per share by 12% in a delight for investors — a good thing, too, since the company’s revenue fell by an ugly 23%, with an ungodly 38% fall in U.S. sales for the quarter. Like Eli Lilly, patent losses took a bite out of the company: Sales of Avapro and Plavix, each which recently lost patent protection, especially hurt, with Plavix revenue falling a ridiculous 97% for the quarter.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!